Choong Ang Vaccine Laboratory Co. Ltd - Asset Resilience Ratio
Choong Ang Vaccine Laboratory Co. Ltd (072020) has an Asset Resilience Ratio of 9.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 072020 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Choong Ang Vaccine Laboratory Co. Ltd's Asset Resilience Ratio has changed over time. See Choong Ang Vaccine Laboratory Co. Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Choong Ang Vaccine Laboratory Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 072020 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.01 Billion | 9.65% |
| Total Liquid Assets | ₩12.01 Billion | 9.65% |
Asset Resilience Insights
- Limited Liquidity: Choong Ang Vaccine Laboratory Co. Ltd maintains only 9.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Choong Ang Vaccine Laboratory Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Choong Ang Vaccine Laboratory Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Choong Ang Vaccine Laboratory Co. Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Choong Ang Vaccine Laboratory Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.21% | ₩13.77 Billion ≈ $9.33 Million |
₩122.82 Billion ≈ $83.23 Million |
-12.44pp |
| 2024-12-31 | 23.65% | ₩29.15 Billion ≈ $19.76 Million |
₩123.28 Billion ≈ $83.54 Million |
+0.72pp |
| 2023-12-31 | 22.93% | ₩27.42 Billion ≈ $18.58 Million |
₩119.59 Billion ≈ $81.05 Million |
+7.27pp |
| 2022-12-31 | 15.66% | ₩17.98 Billion ≈ $12.19 Million |
₩114.86 Billion ≈ $77.84 Million |
-3.35pp |
| 2021-12-31 | 19.00% | ₩21.47 Billion ≈ $14.55 Million |
₩112.95 Billion ≈ $76.55 Million |
-2.68pp |
| 2020-12-31 | 21.69% | ₩22.77 Billion ≈ $15.43 Million |
₩104.98 Billion ≈ $71.14 Million |
+0.22pp |
| 2019-12-31 | 21.47% | ₩20.73 Billion ≈ $14.05 Million |
₩96.57 Billion ≈ $65.44 Million |
-3.62pp |
| 2018-12-31 | 25.09% | ₩24.27 Billion ≈ $16.45 Million |
₩96.74 Billion ≈ $65.56 Million |
+6.69pp |
| 2017-12-31 | 18.40% | ₩15.02 Billion ≈ $10.18 Million |
₩81.62 Billion ≈ $55.32 Million |
-8.91pp |
| 2016-12-31 | 27.31% | ₩20.09 Billion ≈ $13.61 Million |
₩73.54 Billion ≈ $49.84 Million |
+19.11pp |
| 2015-12-31 | 8.21% | ₩5.10 Billion ≈ $3.45 Million |
₩62.10 Billion ≈ $42.09 Million |
+2.19pp |
| 2014-12-31 | 6.02% | ₩3.65 Billion ≈ $2.47 Million |
₩60.60 Billion ≈ $41.07 Million |
-- |
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more